A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
Solid Tumor|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Triple Negative Breast Cancer
DRUG: LY3381916|DRUG: LY3300054
Number of Participants with Dose Limiting Toxicities (DLTs), Number of participants with DLTs, Baseline through Cycle 1 (28 Day Cycle)
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3381916, PK: Cmax of LY3381916, Predose Lead in Day 1 through Cycle 3 Day 1|PK: Area Under the Plasma Concentration Curve (AUC) of LY3381916, PK: AUC of LY3381916, Predose Lead in Day 1 through Cycle 3 Day 1|PK: Cmax of LY3381916 Administered in Combination with LY3300054, PK: Cmax of LY3381916 administered in combination with LY3300054, Predose Cycle 1 Day 1 through Cycle 3 Day 1|PK: AUC of LY3381916 Administered in Combination with LY3300054, PK: AUC of LY3381916 administered in combination with LY3300054, Predose Cycle 1 Day 1 through Cycle 3 Day 1|PK: Cmax of LY3300054 Administered in Combination with LY3381916, PK: Cmax of LY3300054 administered in combination with LY3381916, Predose Cycle 1 Day 1 through Cycle 3 Day 1|PK: Minimum Plasma Concentration (Cmin) of LY3300054 Administered in Combination with LY3381916, PK: Cmin of LY3300054 administered in combination with LY3381916, Predose Cycle 1 Day 1 through Cycle 3 Day 1|Objective Response Rate (ORR): Percentage of Participants with a Complete Response (CR) or Partial Response (PR), ORR: Percentage of participants with a CR or PR, Baseline through Measured Progressive Disease (Estimated up to 12 Months)|Time to Response (TTR), TTR, Baseline to Date of CR or PR (Estimated up to 12 Months)|Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR, DCR: Percentage of participants who exhibit SD, CR or PR, Baseline through Measured Progressive Disease (Estimated up to 12 Months)|Duration of Response (DOR), DOR, Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)|Progression Free Survival (PFS), PFS, Baseline to Objective Progression or Death Due to Any Cause (Estimated Up to 12 Months)
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).